manufacturing industry among the developing countries. Presently‚ the industry meets 97% of local demand and exports to more than 80 countries. The industry has been experiencing robust growth over the last few years. A local industry supporting drug policy and effective regulatory framework‚ along with TRIPS relaxations are the key reasons for success of the industry. While the industry is achieving self-sufficiency‚ it yet procures 70% of raw materials from abroad. But developments are already
Premium Pharmaceutical industry Pharmacology Generic drug
| Corporate Social Responsibility Report: RANBAXY LABORATORIES LTD | | ABSTRACT This report explores the Millennium Development Goals related to Healthcare at global and national level. It also focuses on the diseases that are prevalent in India and the steps taken by Ranbaxy towards the eradication of these diseases. It reviews the activities of Ranbaxy Laboratories towards the welfare of community and the protection of environment. It also throws light on the efforts done by the company in
Premium Millennium Development Goals Mortality rate Malaria
University of Pennsylvania ScholarlyCommons Master of Science in Organizational Dynamics Theses 5-4-2010 Organizational Dynamics Programs Problems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability Donald A. Baines University of Pennsylvania‚ djtz00@aol.com Submitted to the Program of Organizational Dynamics in the Graduate division of the School of Arts and Sciences in Partial Fulfillment of the Requirements for the Degree of Master of Science in the Organizational
Premium Pharmaceutical industry Generic drug
pharmaceutical industry result from high rates of return on investment in R&D also conversely create the incentives necessary to conduct this research. Consumer is sensitive to drug prices. If generic substitute is available it creates high pressure on pricing of product. On other side company is able to charge high premium on patented unique drug. As a whole‚ the industry is highly competitive‚ but individual products are less so due to the number of products that are substitutes for one another
Premium Pharmaceutical industry Pharmacology Generic drug
References: Allasraki‚ M. (2011‚ February 27). The 10 biggest-selling drugs that are about to lose their patent. Retrieved from http: http://www.dailyfinance.com/2011/02/27/top-selling-drugs-are-about-to-lose-patent-protection-ready/ Datamonitor Hoover ’s Company Records. Merck and Co.‚Inc. (2012). Retrieved from http://www.hoovers.com/company/Merck__Co_Inc/rrytji-1-1njhw5.html
Premium Pharmaceutical industry Pharmacology Generic drug
of morality must prevail and this is where the conflict occurs. Do pharmaceutical companies have a responsibility to distribute drugs for free or at low cost in developing countries? How does intellectual property fit in to this quandary? What impact would South Africa’s decision to levy duties on drugs in the country have on the international distribution of drugs? Was the change that provided patent protection for pharmaceutical companies an appropriate change or a dangerous precedent? Was
Premium Pharmaceutical industry Developing country Generic drug
when he ventured on his own to create a history in the Indian Pharmaceutical Industry by choosing Anti-TB as a focused area of operation and went on to make Macleods as one of the major global supplier of entire first line and second line Anti-TB drugs Acuphar division of Macleods Pharmaceuticals deals with the parenteral range of the company which include the majority of Anti-Biotic (First line and second line)‚ NSAIDS‚ and Dry syrup formulations. Brand Preference is Measure of brand loyalty in
Premium Pharmaceutical industry Generic drug Brand
A project report on INTER COMPANY ANALYSIS Analysis of Pharmaceutical Industry in the Indian environment and comparative analysis among Ranbaxy Laboratories Ltd. and Cipla Ltd. Under the guidance of Prof P. Madhavan Visiting Professor‚ IIM Rohtak Undertaken by Ashwani Kumar Atif Aslam Dhiraj Rishiraj Sisodiya Shashi Singh pgp03.016 pgp03.017 pgp03.019 pgp03.054 pgp03.053 This project report is submitted as a partial requirement for the fulfilment of the Business Analysis and Valuation
Premium Financial ratios Financial ratio Generic drug
Formulation and Bulk Drugs Market Share of segments 20% 80% Formulations Bulk Drugs Porter’s 5 forces Threat of Entry: MODERATE Competition: HIGH Porter’s 5 forces Model Threat of substitute: LOW Bargaining power of customers: MODERATE Bargaining power of suppliers: LOW Company Profile: Ranbaxy • Incorporated in 1961. • The largest pharmaceutical company in India and among the top 100 pharmaceuticals companies in the world. • Ranked 8th largest generic drug company in the world
Premium Generic drug Pharmaceutical industry 3rd millennium
innovative processes in which new and better drugs are developed [1]. Those less concerned with the patents for these drugs are concerned about the alarming AIDS statistics‚ which clearly demonstrate the fact that there is an AIDS epidemic in some of the poorest countries in the world. Recovering Expenses In some of the countries where the with AIDS infected population is not only very large but also very poor‚ local companies will reproduce one or more of the drugs that comprise the AIDS “cocktail” and
Premium United Nations AIDS Developing country